Alexander Khoruts

List of Publications by Year in Descending Order

143 papers	13,712 citations	50 h-index	116 g-index
171 ext. papers	16,234 ext. citations	8.6 avg, IF	6.65 L-index

#	Paper	IF	Citations
143	Differential hydrogen sulfide production by a human cohort in response to animal- and plant-based diet interventions.. *Clinical Nutrition*, **2022**, 41, 1153-1162	5.9	0
142	Loss of microbiota-derived protective metabolites after neutropenic fever.. *Scientific Reports*, **2022**, 12, 6244	4.9	1
141	Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1627-1634	6.9	9
140	Microbial Therapeutics in Liver Disease **2021**,		0
139	Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis. *Gut Microbes*, **2021**, 13, 1993584	8.8	0
138	Intermittent Fasting Enhances Right Ventricular Function in Preclinical Pulmonary Arterial Hypertension. *Journal of the American Heart Association*, **2021**, 10, e022722	6	1
137	Circulating Metabolomics Suggest Neutropenic Fever As a Metabolic Derangement Related to Intestinal Tissue Damage and Gut Dysbiosis. *Blood*, **2021**, 138, 688-688	2.2	
136	Gut microbiota response to antibiotics is personalized and depends on baseline microbiota. *Microbiome*, **2021**, 9, 211	16.6	1
135	Methanogen Abundance Thresholds Capable of Differentiating In Vitro Methane Production in Human Stool Samples. *Digestive Diseases and Sciences*, **2021**, 66, 3822-3830	4	2
134	Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. *Mayo Clinic Proceedings*, **2021**, 96, 1418-1425	6.4	3
133	Shotgun sequencing of the faecal microbiome to predict response to steroids in patients with lower gastrointestinal acute graft-versus-host disease: An exploratory analysis. *British Journal of Haematology*, **2021**, 192, e69-e73	4.5	
132	Probiotics and the Microbiome-How Can We Help Patients Make Sense of Probiotics?. *Gastroenterology*, **2021**, 160, 614-623	13.3	8
131	Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials. *Hepatology Communications*, **2021**, 5, 258-271	6	11
130	Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 67-80	24.2	31
129	Structural modifications that increase gut restriction of bile acid derivatives. *RSC Medicinal Chemistry*, **2021**, 12, 394-405	3.5	1
128	Effect of COVID-19 precautions on the gut microbiota and nosocomial infections. *Gut Microbes*, **2021**, 13, 1-10	8.8	2
127	Lower endoscopic delivery of freeze-dried intestinal microbiota results in more rapid and efficient engraftment than oral administration. *Scientific Reports*, **2021**, 11, 4519	4.9	3

126	Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling. *Hepatology*, **2021**, 74, 704-722	11.2	22
125	High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines. *Cell Reports*, **2021**, 37, 109823	10.6	14
124	Altered microbiota-host metabolic cross talk preceding neutropenic fever in patients with acute leukemia. *Blood Advances*, **2021**, 5, 3937-3950	7.8	1
123	Probiotics: Promise, Evidence, and Hope. *Gastroenterology*, **2020**, 159, 409-413	13.3	5
122	Reply to: " R You know my name, but not my story R- Deciding on an accurate nomenclature for faecal microbiota transplantation": Intestinal microbiota transplantation: Naming a new paradigm. *Journal of Hepatology*, **2020**, 72, 1213-1214	13.4	0
121	Sensing of ATP via the Purinergic Receptor P2RX7 Promotes CD8 Trm Cell Generation by Enhancing Their Sensitivity to the Cytokine TGF- *Immunity*, **2020**, 53, 158-171.e6	32.3	25
120	Microbiome swings with repeated insults. *British Journal of Haematology*, **2020**, 189, e94-e96	4.5	0
119	Interactions between the gut microbiome and host gene regulation in cystic fibrosis. *Genome Medicine*, **2020**, 12, 12	14.4	31
118	Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. *Journal of Hepatology*, **2020**, 72, 1003-1027	13.4	65
117	Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease. *Blood*, **2020**, 136, 14-14	2.2	2
116	Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation. *Cancer*, **2020**, 126, 1434-1447	6.4	12
115	Levaquin Gets a Pass. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 778-781	4.7	3
114	Convenient Protocol for Production and Purification of Spores for Germination Studies. *STAR Protocols*, **2020**, 1, 100071	1.4	1
113	Peri-operative antibiotics acutely and significantly impact intestinal microbiota following bariatric surgery. *Scientific Reports*, **2020**, 10, 20340	4.9	3
112	Circulating bacterial DNA and neutropenic fever during anti-leukaemia chemotherapy. *British Journal of Haematology*, **2020**, 191, e55-e58	4.5	
111	Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines. *Clinical Infectious Diseases*, **2020**, 70, 754-762	11.6	20
110	Specific gut microbiota changes heralding bloodstream infection and neutropenic fever during intensive chemotherapy. *Leukemia*, **2020**, 34, 312-316	10.7	13
109	Fecal Microbiota Transplant: A Rose by Any Other Name. *American Journal of Gastroenterology*, **2019**, 114, 1176	0.7	10

108	Letter to the Editor. *Clinical Infectious Diseases*, **2019**, 69, 2232-2233	11.6	1
107	Can intestinal microbiota and circulating microbial products contribute to pulmonary arterial hypertension?. *American Journal of Physiology - Heart and Circulatory Physiology*, **2019**, 317, H1093-H1101	5.2	17
106	Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia. *Scientific Reports*, **2019**, 9, 6083	4.9	18
105	Dietary Factors in Sulfur Metabolism and Pathogenesis of Ulcerative Colitis. *Nutrients*, **2019**, 11,	6.7	19
104	Influence of short-term changes in dietary sulfur on the relative abundances of intestinal sulfate-reducing bacteria. *Gut Microbes*, **2019**, 10, 447-457	8.8	15
103	A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis. *Clinical and Experimental Gastroenterology*, **2019**, 12, 9-19	3.1	33
102	Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 353-361	6.9	33
101	Microbial Exposure Enhances Immunity to Pathogens Recognized by TLR2 but Increases Susceptibility to Cytokine Storm through TLR4 Sensitization. *Cell Reports*, **2019**, 28, 1729-1743.e5	10.6	43
100	Case report of synchronous post-lung transplant colon cancers in the era of colorectal cancer screening recommendations in cystic fibrosis: screening "too early" before it's too late. *BMC Gastroenterology*, **2019**, 19, 137	3	2
99	Durable Long-Term Bacterial Engraftment following Encapsulated Fecal Microbiota Transplantation To Treat Clostridium difficile Infection. *MBio*, **2019**, 10,	7.8	36
98	7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency. *Journal of Medicinal Chemistry*, **2019**, 62, 6824-6830	8.3	8
97	Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy. *PLoS ONE*, **2019**, 14, e0223890	3.7	5
96	Microbiota transplant therapy and autism: lessons for the clinic. *Expert Review of Gastroenterology and Hepatology*, **2019**, 13, 1033-1037	4.2	12
95	Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease. *JCI Insight*, **2019**, 5,	9.9	6
94	Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2019**, 134, 39-39	2.2	
93	The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation. *Journal of Law, Medicine and Ethics*, **2019**, 47, 482-504	1.2	10
92	Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid. *Modern Pathology*, **2019**, 32, 560-567	9.8	5
91	Pre-transplant recovery of microbiome diversity without recovery of the original microbiome. *Bone Marrow Transplantation*, **2019**, 54, 1115-1117	4.4	9

90	Antibiotic-induced Disruption of Intestinal Microbiota Contributes to Failure of Vertical Sleeve Gastrectomy. *Annals of Surgery*, **2019**, 269, 1092-1100	7.8	19
89	Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. *Cell Host and Microbe*, **2018**, 23, 229-240.e5	23.4	177
88	Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. *Gastroenterology*, **2018**, 154, 736-745.e14	13.3	75
87	Functional Genomics of Host-Microbiome Interactions in Humans. *Trends in Genetics*, **2018**, 34, 30-40	8.5	41
86	Reply. *Gastroenterology*, **2018**, 154, 2283-2284	13.3	
85	Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2190-2196	4.7	7
84	CLOUD: a non-parametric detection test for microbiome outliers. *Microbiome*, **2018**, 6, 137	16.6	3
83	Gastrointestinal cancers in patients with cystic fibrosis. *Lancet Oncology, The*, **2018**, 19, e368	21.7	5
82	Colorectal cancer mutational profiles correlate with defined microbial communities in the tumor microenvironment. *PLoS Genetics*, **2018**, 14, e1007376	6	41
81	Elevated AREG/EGF Ratio Prior to Transplantation Is Associated with Pre-Transplant Clostridium Difficile Infection, Unresolved Tissue Damage, and Poorer Overall Survival. *Blood*, **2018**, 132, 3353-3353	2.2	0
80	Low Amphiregulin Expression in Intestinal Biopsies of Patients with Acute Graft-Versus-Host Disease. *Biology of Blood and Marrow Transplantation*, **2018**, 24, S188	4.7	3
79	Clinician Guide to Microbiome Testing. *Digestive Diseases and Sciences*, **2018**, 63, 3167-3177	4	12
78	Targeting the microbiome: from probiotics to fecal microbiota transplantation. *Genome Medicine*, **2018**, 10, 80	14.4	22
77	Predicting recurrence of Clostridium difficile infection following encapsulated fecal microbiota transplantation. *Microbiome*, **2018**, 6, 166	16.6	49
76	Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. *Gut Microbes*, **2017**, 8, 303-309	8.8	50
75	Sleeve gastrectomy drives persistent shifts in the gut microbiome. *Surgery for Obesity and Related Diseases*, **2017**, 13, 916-924	3	32
74	Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. *Microbiome*, **2017**, 5, 10	16.6	595
73	Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota. *Gut Microbes*, **2017**, 8, 276-288	8.8	25

72	Infection Followed by Graft-versus-Host Disease: Pathogenic Role of Antibiotics. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1038-1039	4.7	4
71	Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study. *American Journal of Gastroenterology*, **2017**, 112, 940-947	0.7	109
70	Fecal microbiota transplantation-early steps on a long journey ahead. *Gut Microbes*, **2017**, 8, 199-204	8.8	2
69	Synthesis and Biological Evaluation of Bile Acid Analogues Inhibitory to Clostridium difficile Spore Germination. *Journal of Medicinal Chemistry*, **2017**, 60, 3451-3471	8.3	25
68	Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. *Microbiome*, **2017**, 5, 55	16.6	74
67	Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 522-528	5.1	6
66	Analysis of gut microbiota - An ever changing landscape. *Gut Microbes*, **2017**, 8, 268-275	8.8	18
65	Defining total-body AIDS-virus burden with implications for curative strategies. *Nature Medicine*, **2017**, 23, 1271-1276	50.5	214
64	Stable engraftment of human microbiota into mice with a single oral gavage following antibiotic conditioning. *Microbiome*, **2017**, 5, 87	16.6	77
63	Contemporary Applications of Fecal Microbiota Transplantation to Treat Intestinal Diseases in Humans. *Archives of Medical Research*, **2017**, 48, 766-773	6.6	20
62	Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota. *Translational Research*, **2017**, 179, 116-125	11	15
61	Interaction of gut microbiota with bile acid metabolism and its influence on disease states. *Applied Microbiology and Biotechnology*, **2017**, 101, 47-64	5.7	235
60	Identification of p-cresol sulfate and secondary bile salts in human urine as sensitive biomarkers of fecal microbiota transplantation in R-CDI patients. *FASEB Journal*, **2017**, 31, 315.1	0.9	
59	Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial. *Annals of Internal Medicine*, **2016**, 165, 609-616	8	344
58	Faecal microbiota transplantation is promising but not a panacea. *Nature Microbiology*, **2016**, 1, 16015	26.6	20
57	Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection. *Journal of Clinical Gastroenterology*, **2016**, 50, 624-30	3	69
56	Understanding the mechanisms of faecal microbiota transplantation. *Nature Reviews Gastroenterology and Hepatology*, **2016**, 13, 508-16	24.2	245
55	First microbial encounters. *Nature Medicine*, **2016**, 22, 231-2	50.5	5

54	Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1433-8	6.9	149
53	Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth. *PLoS ONE*, **2016**, 11, e0147210	3.7	90
52	Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation. *MBio*, **2016**, 7,	7.8	66
51	Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis. *Journal of Cystic Fibrosis*, **2016**, 15, 548-53	4.1	39
50	Environmental Contamination in Households of Patients with Recurrent Clostridium difficile Infection. *Applied and Environmental Microbiology*, **2016**, 82, 2686-2692	4.8	23
49	Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. *Microbiome*, **2015**, 3, 10	16.6	175
48	Mast Cell Activation Disease and Microbiotic Interactions. *Clinical Therapeutics*, **2015**, 37, 941-53	3.5	13
47	Development of fecal microbiota transplantation suitable for mainstream medicine. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 246-50	6.9	32
46	Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E1126-34	11.5	189
45	Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions. *Journal of Infectious Diseases*, **2015**, 211, 1068-75	7	35
44	From stool transplants to next-generation microbiota therapeutics. *Gastroenterology*, **2014**, 146, 1573-1582	13.3	129
43	Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. *American Journal of Physiology - Renal Physiology*, **2014**, 306, G310-9	5.1	254
42	Faecal microbiota transplantation in 2013: developing human gut microbiota as a class of therapeutics. *Nature Reviews Gastroenterology and Hepatology*, **2014**, 11, 79-80	24.2	12
41	Human microbiome science: vision for the future, Bethesda, MD, July 24 to 26, 2013. *Microbiome*, **2014**, 2,	16.6	18
40	Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. *Microbiome*, **2014**, 2, 13	16.6	77
39	Emergence of fecal microbiota transplantation as an approach to repair disrupted microbial gut ecology. *Immunology Letters*, **2014**, 162, 77-81	4.1	32
38	Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. *American Journal of Gastroenterology*, **2014**, 109, 1065-71	0.7	426
37	Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 283-8	6.9	46

36	Fecal microbiota transplantation: an interview with alexander khoruts. *Global Advances in Health and Medicine*, **2014**, 3, 73-80	1.9	2
35	Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 2307-12	11.5	458
34	Introduction to special issue on microbiome influences on host immunity. *Immunology Letters*, **2014** , 162, 1-2	4.1	
33	Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. *Journal of Clinical Gastroenterology*, **2014**, 48, e85-8	3	32
32	Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. *Journal of Clinical Gastroenterology*, **2013**, 47, 735-7	3	71
31	High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. *Gut Microbes*, **2013**, 4, 125-35	8.8	218
30	Fecal Microbiota Transplantation (FMT) for Treatment of Clostridium difficile Infection (CDI) in Immunocompromised Patients: ACG Governors Award for Excellence in Clinical Research. *American Journal of Gastroenterology*, **2013**, 108, S179-S180	0.7	4
29	Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. *American Journal of Gastroenterology*, **2012**, 107, 761-7	0.7	466
28	Fecal microbiota transplantation and emerging applications. *Nature Reviews Gastroenterology and Hepatology*, **2011**, 9, 88-96	24.2	411
27	Treating Clostridium difficile infection with fecal microbiota transplantation. *Clinical Gastroenterology and Hepatology*, **2011**, 9, 1044-9	6.9	664
26	Therapeutic transplantation of the distal gut microbiota. *Mucosal Immunology*, **2011**, 4, 4-7	9.2	66
25	Induction of TGF-beta1 and TGF-beta1-dependent predominant Th17 differentiation by group A streptococcal infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 5937-42	11.5	70
24	CD4+CD25+Foxp3+ regulatory T cells optimize diversity of the conventional T cell repertoire during reconstitution from lymphopenia. *Journal of Immunology*, **2010**, 184, 4749-60	5.3	30
23	Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. *Journal of Clinical Gastroenterology*, **2010**, 44, 354-60	3	499
22	Regulatory CD4+CD25+Foxp3+ T cells selectively inhibit the spontaneous form of lymphopenia-induced proliferation of naive T cells. *Journal of Immunology*, **2008**, 180, 7305-17	5.3	55
21	De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. *Journal of Leukocyte Biology*, **2008**, 83, 1230-9	6.5	99
20	High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage. *Mucosal Immunology*, **2008**, 1, 49-58	9.2	68
19	Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. *Blood*, **2008**, 112, 2826-35	2.2	496

18	MHC class II deprivation impairs CD4 T cell motility and responsiveness to antigen-bearing dendritic cells in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 7181-6	11.5	57
17	Naive and memory CD4+ T cell survival controlled by clonal abundance. *Science*, **2006**, 312, 114-6	33.3	288
16	A causal link between lymphopenia and autoimmunity. *Immunology Letters*, **2005**, 98, 23-31	4.1	101
15	A model of suppression of the antigen-specific CD4 T cell response by regulatory CD25+CD4 T cells in vivo. *International Immunology*, **2005**, 17, 335-42	4.9	6
14	A role for CD28 in lymphopenia-induced proliferation of CD4 T cells. *Journal of Immunology*, **2004**, 173, 3909-15	5.3	47
13	CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. *Journal of Experimental Medicine*, **2004**, 200, 749-59	16.6	1393
12	IL-1 acts on antigen-presenting cells to enhance the in vivo proliferation of antigen-stimulated naive CD4 T cells via a CD28-dependent mechanism that does not involve increased expression of CD28 ligands. *European Journal of Immunology*, **2004**, 34, 1085-90	6.1	33
11	Competition for self ligands restrains homeostatic proliferation of naive CD4 T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 1185-90	11.5	103
10	Visualizing the generation of memory CD4 T cells in the whole body. *Nature*, **2001**, 410, 101-5	50.4	846
9	Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. *Journal of Immunology*, **2001**, 167, 5636-44	5.3	71
8	Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. *Journal of Immunology*, **2001**, 167, 188-95	5.3	370
7	Homeostatic expansion occurs independently of costimulatory signals. *Journal of Immunology*, **2001**, 167, 5664-8	5.3	103
6	In vivo activation of antigen-specific CD4 T cells. *Annual Review of Immunology*, **2001**, 19, 23-45	34.7	403
5	Antigen-experienced CD4 T cells display a reduced capacity for clonal expansion in vivo that is imposed by factors present in the immune host. *Journal of Immunology*, **2000**, 164, 4551-7	5.3	55
4	CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. *Immunity*, **1999**, 11, 483-93	32.3	260
3	A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. *Journal of Experimental Medicine*, **1998**, 187, 225-36	16.6	193
2	In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. *Journal of Experimental Medicine*, **1997**, 185, 2133-41	16.6	462
1	Use of adoptive transfer of T-cell-antigen-receptor-transgenic T cell for the study of T-cell activation in vivo. *Immunological Reviews*, **1997**, 156, 67-78	11.3	185